Time-Point: Tanespimycin In Myeloma Evaluation: Performance of HSP 90 Inhibitor As Initial Therapy Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 11 years ago on Monday, September 10, 2012, according to the United State Patent & Trademark Office
Word Mark Time-Point: Tanespimycin in Myeloma Evaluation: Performance of Hsp 90 Inhibitor as Initial Therapy
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77795574
Status Date Monday, September 10, 2012
Filing Date Monday, September 10, 2012
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154

Case File Statements

Disclaimer with Predetermined Text "Tanespimycin in Myeloma Evaluation: Performance of Hsp 90 Inhibitor as Initial Therapy"
Goods & Services Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Thursday, August 6, 2009
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.